- $231.17m
- $160.89m
- $194.06m
Annual cashflow statement for LifeMD, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -61.3 | -45 | -17.8 | -18.7 | 15.6 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 18.2 | 18.6 | 14.6 | 14.1 | -6.8 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 9.13 | -0.661 | 5.49 | 12.6 | -7.85 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -33.1 | -22.9 | 8.82 | 17.5 | 8.28 |
| Capital Expenditures | -3.38 | -8.89 | -8.58 | -11.5 | -9.52 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | -0.022 | -5.01 | -0.149 | -0.004 | 16.4 |
| Acquisition of Business | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.4 | -13.9 | -8.73 | -11.5 | 6.91 |
| Financing Cash Flow Items | -0.444 | -0.288 | -0.762 | -0.805 | -0.774 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 68.6 | -0.528 | 29.1 | -4.12 | -13.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 32.1 | -37.4 | 29.2 | 1.86 | 1.78 |